Annual Real World Evidence Conference: Applying Lessons Learned from RWE in the Time of COVID-19 to the Future

Event

COVID-19 Response

Annual Real World Evidence Conference: Applying Lessons Learned from RWE in the Time of COVID-19 to the Future

Register

OVERVIEW

COVID-19 has disrupted the evidence-generation paradigm, resulting in the expanded use of novel technologies, data, and evidence. These new advancements not only improve clinical care and medical product development to fight the pandemic, but also have the potential to inform the future of drug development more broadly. This meeting will explore how COVID-19 has accelerated decision-maker understanding and use of real-world data (RWD) and real-world evidence (RWE) and its application in a post-COVID-19 environment. 

 

 

 

Funding for this conference is made possible through the generosity of the Margolis Family Foundation, which provides core resources for the Center, as well as a combination of financial and in-kind contributions from RWE Collaborative members including AbbVie; Amgen; Eli Lilly and Company; Pfizer; Genentech, a member of the Roche Group; GlaxoSmithKline; Merck; Novartis; Teva and UCB.